步長製藥(603858.SH):全資子公司藥品生產許可證變更
格隆匯3月28日丨步長製藥(603858.SH)公佈,獲悉全資子公司山東丹紅製藥有限公司獲得山東省藥品監督管理局許可,同意公司《藥品生產許可證》副本增加車間及委託生產產品批准文號信息,其他內容不變。經審查、技術審評和GMP符合性檢查,在生產地址:菏澤牡丹工業園區昆明路99號,新增製劑I車間(小容量注射劑生產線),生產範圍:小容量注射劑。委託山東步長製藥股份有限公司生產的地氯雷他定片(國藥準字H20223419)、普瑞巴林膠囊(國藥準字H20234016)、普瑞巴林膠囊(國藥準字H20234017)獲得藥品上市許可,增加批准文號信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.